Activation of mammalian target of rapamycin in diffuse large B-cell lymphoma: A clinicopathological study

Leukemia Research

Volumn 36, Issue 11, 2012, Pages 1403-1409

  Vajpayee, Neerja ^a   Thakral, Charu ^a   Gopaluni, Srivalli ^a   Newman, Nancy ^a   Gajra, Ajeet ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Diffuse large B cell lymphoma; MTOR expression

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN; PREDNISONE; PROTEIN BCL 2; PROTEIN SERINE THREONINE KINASE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SURVIVAL TIME;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84866341712     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.07.016     Document Type: Article

References (36)

1. The Non-Hodgkin's Lymphoma Classification Project A clinical evaluation of the International Lymphoma Study Group classification of Non-Hodgkin's, lymphoma. Blood 1997, 89:3909-3916.
2. Muris J.J., Cillessen S.A., Vos W., et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 2005, 105:2916-2923.
3. Uddin S., Hussain A.R., Siraj A.K., et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006, 108(13):4178-4186.
4. Pandolfi P.P. Breast cancer-loss of PTEN predicts resistance to treatment. New Engl J Med 2004, 35:2337-2338.
5. Saal L.H., Holm K., Maurer M., et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65:2554-2559.
6. Zhang P., Ostrander J.H., Faivre E.J., Olsen A., Fitzsimmons D., Lange C.A. Regulated association of protein kinase B/Akt with breast tumor kinase. J Biol Chem 2005, 280:1982-1991.
7. Fingar D.C., Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23:3151-3171.
8. Panwalkar A., Verstovsek S., Giles F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004, 100:657-666.
9. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121:179-193.
10. Sekulic A., Hudson C.C., Homme J.L., et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000, 60:3504-3513.
11. Witzig T.E., Kaufmann S.H. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 2006, 7:285-294.
12. Gupta M., Ansell S.M., Novak A.J., Kumar S., Kaufmann S.H., Witzig T.E. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009, 114(October (14)):2926-2935.
13. Wlodarski P., Kasprzycka M., Liu X., et al. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase, insulin growth factor-I, and serum. Cancer Res 2005, 65:7800-7808.
14. Dowling R.J., Topisirovic I., Fonseca B.D., Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta 2010, 1804:433-439.
15. Witzig T.E., Reeder C.B., LaPlant B.R., et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011, 25:341-347.
16. Recher C., Beyne-Rauzy O., Demur C., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005, 105:2527-2534.
17. Hipp S., Ringshausen I., Oelsner M., Bogner C., Peschel C., Decker T. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 2005, 90:1433-1434.
18. Witzig T.E., Geyer S.M., Ghobrial I., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005, 23:5347-5356.
19. Feng W., Duan X., Liu J., Xiao J., Brown R. Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous Carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol 2009, 2:249-260.
20. Herberger B., Puhalla H., Lehnert M., et al. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 2007, 13(16):4795-4800.
21. Sahin F., Kannangai r., Adegbola O., Wang J., Su G., Torbenson M. mTOR and P70 s6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004, 10:8421-8425.
22. Dobashi Y., Suzuki S., Matsubara H., Kimura M., Endo S., Ooi A. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer 2009, 115:107-118.
23. Gupta M., Ansell S.M., Novak A.J., Kumar S., Kaufmann S.H., Witzig T.E. JT Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009, 114:2926-2935.
24. Leseux L., Hamdi S.M., Saati T.A., et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006, 108(13):4156-4162.
25. WHO classification of tumors of haematopoietic and lymphoid tissues 2008, IARC, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
26. Bhatt A.P., Bhende P.M., Sin S.H., Roy D., Dittmer D.P., Damania B. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 2010, 115:4455-4463.
27. Pavan A., Spina M., Canzonieri V., Sansonno S., Toffoli G., De Re V. Prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies. Leuk Lymphoma 2008, 49(November (11)):2048-2058.
28. Seki R., Ohshima K., Fujisaki T., et al. Okamur. Prognostic impact of immunohistochemical bio markers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2009, 100(October (10)):1842-1847.
29. Yu B.H., Zhou X.Y., Xiao X.Y., Yan S.Y., Qin T., Shi D.R. Activation and clinicopathologic significance of AKT/mTOR signaling pathway in diffuse large B-cell lymphoma. Zhonghua Bing Li Xue Za Zhi 2009, 38(1):35-41. [in Chinese].
30. Wanner K., Hipp S., Oelsner M., et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Brit J Hematol 2006, 134(September (5)):475-484.
31. Zhuo L., Cai G., Liu F., et al. Expression and mechanism of mammalian target of rapamycin in age related renal cell senescence and organ aging. Mech Ageing Dev 2009, 130(October (10)):700-708.
32. No J.H., Jeon Y.T., Park I.A., et al. Expression of mTOR protein and its clinical significance in endometrial cancer. Med Sci Monit 2009, 15(October (10)):BR301-BR305.
33. Gascoyne R.D., Adomat S.A., Krajewski S., et al. Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive Non-Hodgkin's Lymphoma. Blood 1997, 90:244-251.
34. Iqbal J., Neppalli V.T., Wright G., et al. Bcl-2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006, 24(6):961-968.
35. Witzig T.E., Gupta M. Signal transduction inhibitor therapy for lymphoma. Hematology 2010, 265-270. American Society of Hematology Education Program Book.
36. Zhao M.Y., Auerbach A., D'Costa A.M., et al. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. Clin Cancer Res 2001, 15(March (5)):1708-1720.